sorafenib has been researched along with ovatodiolide in 2 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (ovatodiolide) | Trials (ovatodiolide) | Recent Studies (post-2010) (ovatodiolide) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 31 | 0 | 25 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bamodu, OA; Chang, HL; Chen, HA; Lee, KF; Lee, WH; Tsai, JT; Tzeng, YM | 1 |
| Chen, MY; Chu, YC; Hsieh, MS; Hsu, CH; Ma, HP; Ong, JR; Setiawan, SA; Tzeng, DTW; Tzeng, YM; Wu, ATH; Yeh, CT | 1 |
2 other study(ies) available for sorafenib and ovatodiolide
| Article | Year |
|---|---|
Ovatodiolide suppresses yes-associated protein 1-modulated cancer stem cell phenotypes in highly malignant hepatocellular carcinoma and sensitizes cancer cells to chemotherapy in vitro.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Carcinoma, Hepatocellular; Diterpenes; Endoplasmic Reticulum Chaperone BiP; Humans; Liver Neoplasms; Neoplastic Stem Cells; Niacinamide; Phenotype; Phenylurea Compounds; Phosphoproteins; Sorafenib; Transcription Factors; YAP-Signaling Proteins | 2018 |
Ovatodiolide and antrocin synergistically inhibit the stemness and metastatic potential of hepatocellular carcinoma via impairing ribosome biogenesis and modulating ERK/Akt-mTOR signaling axis.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Diterpenes; Humans; Lactones; Liver Neoplasms; Mice; Neoplastic Stem Cells; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Ribosomes; Sesquiterpenes; Sorafenib; TOR Serine-Threonine Kinases | 2023 |